CORRIGENDUM**Opportunities for therapeutic antibodies directed at G-protein-coupled receptors***Catherine J. Hutchings, Markus Koglin, William C. Olson and Fiona H. Marshall*Nature Reviews Drug Discovery **16** (2017)

In the article, the clinical trial for the biparatopic CXCR2 nanobody was described as being for cancer instead of inflammation. This error has been corrected in the online version.